Meso
Aftermath
Archived
Pharma M&A: bulking up cancer pipelines
Activity declining — narrative losing relevance.
Score
0.3
Velocity
▲ 0.0
Articles
6
Sources
2
Sentiment Timeline
Event Timeline
Apr 11, 2026
Gilead Sciences (GILD) to Acquire Tubulis for $5B to Strengthen Oncology Pipeline
Bullish
Hypotheses
Pending
Due: Aug. 22, 2026
Merck's R&D spending as percentage of revenue will increase by 50-100 basis points in fiscal 2025 due to integration of Terns' development programs and pipeline advancement costs
Pending
Due: Sept. 21, 2026
Merck's oncology revenue segment will grow at ≥8% year-over-year in the next 2 fiscal years (2025-2026) as Terns' pipeline assets contribute to marketed products and late-stage development candidates
Pending
Due: June 23, 2026
Merck's acquisition of Terns Pharmaceuticals will drive MRK stock outperformance by at least 5% relative to S&P 500 within 90 days post-announcement due to positive market sentiment toward cancer pipeline expansion
🤖
AI Overview
What happened: Gilead Sciences (GILD) acquired German biotech Tubulis for up to $5B, strengthening its oncology pipeline. Merck & Co. (MRK) bought Terns Pharmaceuticals for $6.7B to bolster its cancer portfolio before Keytruda's patent expires in 2028. Gilead's and Merck's deals follow a trend of big pharma acquisitions in the oncology space, with Novartis also buying Excellergy for up to $2B.
Market impact: These acquisitions drive M&A activity in the biotech and pharma sectors, particularly in oncology. They signal a focus on beefing up pipelines and preparing for patent expirations. The deals could lead to valuation repricing in targeted biotechs and increased competition in cancer drug development.
What to watch next: Gilead's and Merck's earnings calls (Q2 2023) for updates on integration and pipeline progress. Also, monitor the U.S. FDA's decisions on Keytruda's indications and any potential new approvals for Gilead's and Merck's acquired assets.
Market impact: These acquisitions drive M&A activity in the biotech and pharma sectors, particularly in oncology. They signal a focus on beefing up pipelines and preparing for patent expirations. The deals could lead to valuation repricing in targeted biotechs and increased competition in cancer drug development.
What to watch next: Gilead's and Merck's earnings calls (Q2 2023) for updates on integration and pipeline progress. Also, monitor the U.S. FDA's decisions on Keytruda's indications and any potential new approvals for Gilead's and Merck's acquired assets.
AI Overview as of Apr 11, 2026
Timeline
First SeenMar 25, 2026
Last UpdatedMar 25, 2026